Galapagos NV (LTS:0JXZ) Total Equity : €2,795.6 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Galapagos NV Total Equity?

Galapagos NV's total equity for the quarter that ended in Dec. 2023 was €2,795.6 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Galapagos NV Total Equity Historical Data

The historical data trend for Galapagos NV's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Total Equity Chart

Galapagos NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Equity

Get a 7-Day Free Trial

2,875.66

2,670.36

2,643.36

2,526.03

2,795.57

Galapagos NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Equity	Get a 7-Day Free Trial															2,526.03	2,564.60	2,583.95	2,621.56	2,795.57

Galapagos NV Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Galapagos NV's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	4357.396	-	1561.83
	=	2,795.6

Galapagos NV's Total Equity for the quarter that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	4357.396	-	1561.83
	=	2,795.6

Galapagos NV Total Equity Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV (LTS:0JXZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (LTS:0JXZ) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

GLPG:USA GLPG:Netherlands GLPG:Mexico GXE:Germany GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Galapagos NV (LTS:0JXZ) Headlines

No Headlines